Physician profile
James C Bigham
NPI 1962837245
$11,620.96
in general payments reported to CMS, 2019-2025
48 companies · $2,016 in 2025
The $2,016 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,380 · 2022: $2,008 · 2023: $2,097 · 2024: $2,120 · 2025: $2,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,232.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,682.31 | 2021-2025 | General - Pain Management, Intracept, Entrada |
| Collegium Pharmaceutical, INC. | $1,637.59 | 2021-2025 | Xtampza, Belbuca |
| Biohaven Pharmaceuticals, INC. | $1,227.95 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $985.13 | 2021-2025 | Relistor |
| Pfizer INC. | $464.42 | 2021-2025 | |
| Scilex Pharmaceuticals INC. | $388.14 | 2021-2024 | Ztlido |
| Relievant Medsystems, INC. | $365.00 | 2023 | Intracept |
| Abbvie INC. | $362.37 | 2021-2025 | |
| Almatica Pharma LLC | $348.41 | 2021-2023 | Gralise |
| Vertos Medical, INC. | $324.97 | 2023-2024 | Mild Device Kit |
| Biodelivery Sciences International, INC. | $316.78 | 2021 | |
| Nalu Medical, INC. | $301.43 | 2021-2024 | Nalu Neurostimulation System |
| Axsome Therapeutics, INC. | $290.89 | 2025 | Symbravo |
| Axonics, INC. | $289.04 | 2024 | Axonics |
| Medtronic, INC. | $267.80 | 2023-2025 | Synchromedii, Intellis Adaptivestim |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $235.56 | 2021-2022 | |
| Ibsa Pharma INC. | $207.00 | 2021-2024 | Tirosint, Licart, Tirosint |
| Lilly USA, LLC | $203.86 | 2021-2023 | Emgality, Reyvow |
| Grt US Holding, INC. | $193.68 | 2021-2022 | |
| Protega Pharmaceutials INC | $181.36 | 2023-2024 | Roxybond |
| Hikma Pharmaceuticals USA | $171.70 | 2021-2024 | Kloxxado |
| Spr Therapeutics, INC | $142.75 | 2023 | Sprint Pns System |
| Biohaven Pharmaceutical Holding Company LTD. | $122.04 | 2022 | |
| Valinor Pharma, LLC | $112.96 | 2023-2024 | Movantik |
| Nevro Corp. | $85.08 | 2022 | |
| Stryker Corporation | $69.03 | 2021-2024 | Mild Device Kit |
| Teva Pharmaceuticals USA, INC. | $61.43 | 2025 | Ajovy |
| Alnylam Pharmaceuticals INC. | $60.18 | 2022 | |
| Horizon Therapeutics Plc | $47.70 | 2021-2022 | |
| Convatec INC. | $47.09 | 2025 | |
| Supernus Pharmaceuticals, INC. | $35.79 | 2021 | |
| Mml US, INC. | $35.10 | 2025 | Reactiv8 |
| Uswm, LLC | $31.22 | 2021 | |
| Biotronik Nro, INC. | $30.73 | 2024-2025 | Prospera |
| Redhill Biopharma INC. | $29.12 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $24.85 | 2024 | Crysvita |
| Abbott Laboratories | $24.57 | 2024 | Proclaim |
| Averitas Pharma INC. | $24.47 | 2024 | Qutenza |
| Amgen INC. | $24.32 | 2022 | |
| Arbor Pharmaceuticals, INC. | $24.01 | 2021 | |
| Orthogenrx INC. | $21.21 | 2021 | |
| Atland Pharmaceuticals, LLC | $21.17 | 2024 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Allergan, INC. | $19.46 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.18 | 2023 | |
| Virtus Pharmaceuticals LLC | $16.76 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $16.29 | 2025 | |
| Painteq LLC | $15.84 | 2024 | Painteq |
| Azurity Pharmaceuticals, INC. | $13.22 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bigham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.